Unlocking the health benefits of cannabinoids.

Sanity Group and the Swiss Institute for Addiction and Health Research (ISGF) received final approval from the Swiss Federal Office of Public Health (BAG) to conduct a study on the controlled dispensing of recreational cannabis in the canton of Basel-Landschaft, Switzerland. The aim of the study is to learn more about the effects of controlled access to cannabis and thus provide a solid scientific basis for possible decisions on future cannabis regulation in Switzerland. The study with the title “Grashaus Projects” is scheduled to launch later this year. It will initially be dispensed through an initial store in the municipality of Allschwil, with another location in Liestal to follow. Sanity Group is the only German company participating in the Swiss pilot projects.

Last week, the German government presented the official draft bill for pillar 1 (cannabis clubs & decriminalization) of the planned cannabis legalization in Germany. We have taken an in-depth look at the draft – it contains many good approaches, some parts we still see critically. A brief assessment.

The medical division of Berlin-based cannabis company Sanity Group, one of Germany’s leading suppliers of medical cannabis, is initiating international business operations through the launch of exclusive distribution partnerships in Switzerland, Portugal, Poland and Malta.